Rubella is usually a mild, febrile rash illness in children and adults; however, intrauterine rubella virus infection during the first trimester of pregnancy can cause miscarriage, stillbirth, or a constellation of birth defects known as congenital rubella syndrome (CRS). The most common congenital defects associated with CRS are cataract(s), heart defects, and hearing impairment [1] [2] . The lifetime cost of treating a child born with CRS in an industrialized country is estimated to exceed $200,000 [3] .
Implementation of vaccination strategies for rubella control and congenital rubella prevention in the World Health Organization (WHO) European Region has resulted in record low levels of disease [4] . By 2009, all 53 Member States had incorporated a rubella-containing vaccine into their routine childhood immunization programs through the use of combined vaccines that contain either measles and rubella (MR) or measles, mumps, and rubella (MMR) components, and all Member States have supported the goals of measles and rubella elimination and CRS prevention. Integration of measles and rubella surveillance is recommended in WHO Regions with rubella goals because of the use of these combined vaccines and because of the similarities in clinical manifestations of the diseases and laboratory testing methodology using the enzyme-linked immunosorbant assay [5] .
Poland has a population of 38.5 million individuals, with an estimated birth cohort of 385,000 persons annually [6] . The country consists of 16 administrative units, with populations ranging of 1-5 million persons each and is divided into 379 districts. The history of measles-and rubella-containing vaccine recommendations has varied by age and sex in Poland during the past 30 years (Table 1) .
During 2003-2005, Poland reported elimination-suggestive sustained annual measles incidence of ,1 locally acquired case per 1,000,000 population [7, 8] . Annual measles incidence since 2005 has been ,6 cases per 1,000,000 population primarily because of importations, with virus circulating primarily among unvaccinated specific populations, such as the Roma communities [7] . However, rubella incidence has not reached ,100 cases per 1,000,000 population annually, and epidemics throughout the country are still reported.
Because of sustained high rates of rubella incidence in Poland, a WHO and Centers for Disease Control and Prevention mission was conducted in 2009 to review rubella and CRS surveillance data and to assist the national immunization program to develop evidence-based recommendations aimed at achieving WHO European Regional elimination goals. In this article, we used national surveillance data to describe rubella epidemiology in Poland and to discuss optimal approaches to reaching rubella elimination, including integrating measles and rubella program activities.
METHODS

Reported Rubella and CRS Cases
National rubella and CRS surveillance in Poland is based on a mandatory reporting system of cases from provinces since 1966 and 1997, respectively. Each district has a Territorial Health Department that receives rubella case report forms from primary health care providers in hospitals, polyclinics, diagnostic centers, or other health care facilities. Information collected includes patient name, age, date of birth, sex, and vaccination status. These data are aggregated at the district level into specified age groups (individual years of age 0-9 years, 5-year age groups for 10-59 years, and a single group aged .60 years), stratified by sex, and reported bi-weekly to the Provincial Health Department. Aggregated data from the provincial level are then reported at the national level.
We assessed nationwide rubella incidence during 1966-2008, calculated per 1,000,000 population, with use of Census data from the Central Statistical Office in Warsaw. Annual aggregated data were analyzed by age, sex, and vaccination status since the first dose MMR vaccine recommendation was made in 2003. To assess overall differences in disease among male and female persons by age group, incidence among male and female persons in the 9 age strata was calculated per 10,000 population, and relative risks (RRs) with 95% confidence intervals (CIs) were estimated using a negative-binomial model. Population sizes for each region were used as offsets for the various age and sex strata.
For more detailed analysis of rubella epidemiology during 2006-2008, the years with the highest incidence since 2003, we obtained rubella case-based data from 4 geographically separated provinces (representing 31% of the total population). Case-based data were assessed by age, sex, vaccination status, and laboratory status. We also used the case-based data to conduct an individual birth cohort analysis for age groups with the highest proportion of cases and assessed the percentage of all cases by birth year among male and female individuals during 2006-2008.
We described the reported number of cases of CRS since 1997 and assessed maternal eligibility for receipt of vaccine. We obtained fertility rate data from the Central Statistical Office and births by maternal age from national statistics in Poland.
Vaccination Coverage
Vaccination coverage data in Poland is based on annual reports of immunization providers, who record the number of doses administered by birth cohort. Filling the immunization information on individual patient vaccination cards is compulsory for use of state-refunded vaccines. We reviewed data on Poland's vaccination coverage available at the National Institute of Public Health and National Institute of Hygiene (NIPH-NIH), Warsaw, for monovalent rubella vaccine among girls aged 15 years during 1992-2006 (the time frame and age of coverage availability) and on first dose MMR since the recommendations during 2005-2008.
RESULTS
Reported Rubella Cases
Nationwide Incidence of Rubella, 1966 -2008 . During 1966 -2008 , the reported incidence of rubella in Poland ranged from Demographic characteristics of rubella cases are provided in Table 2 . Overall, 64% of cases were in male individuals, increasing from 56% in 2003 to 73% in 2008. Figure 2 shows the overall incidence among male and female individuals and the corresponding RRs and 95% CIs for male versus female individuals for 5-year age cohorts from 0-39 years and for all persons aged R40 years. Incidence was highest among male and female individuals 5-9 years of age and remained high among male individuals through 19 years of age. The risk was higher among male individuals 10-24 years of age but was higher among all female individuals aged .30 years. RR trends by age groups and sex were similar before (during [2003] [2004] [2005] 16,106 case patients (83%); of these, 2255 (14%) reported having received a single dose of vaccine, 161 (1%) had received 2 doses, and 13,690 (85%) had never been vaccinated. Each year, ,1% of reported cases were laboratory confirmed. 
Reported CRS Cases
During 1997-2008, 18 CRS cases were reported in Poland, ranging from 5 cases in 1997 to no cases during [2003] [2004] [2005] [2006] . The majority of cases were identified through detection of congenital malformations of live newborns or during infancy. According to the infant year of birth and maternal age, 6 (33%) of the mothers of infants with CRS cases had been eligible to receive RCV as an adolescent but had not been vaccinated ( Results of this assessment indicate that, among adolescents, the risk of rubella in Poland is higher among boys than among girls; however, among persons .30 years of age, women are at a higher risk than men. Seroepidemiologic data from Poland collected during 2000-2002 indicate that rubella susceptibility among women of childbearing age was 16%-21% [9] . Data from other countries indicate that CRS cases can occur even in small cohorts of rubella-susceptible women of childbearing age [10] [11] [12] . Of the 3 Latin American countries (Argentina, Brazil, and Chile) that conducted MMR campaigns targeting only adolescent and adult female cohorts, rubella remained endemic, with outbreaks among adolescent and adult male cohorts, and CRS cases continued to occur. To stop the outbreaks, Argentina and Chile conducted successful campaigns targeted to adolescent and adult male cohorts [13, 14] . In addition, Brazil conducted a MMR campaign targeting 70 million male and female adolescent and adult cohorts.
Despite long-standing efforts to vaccinate adolescent girls, high disease transmission across wide age ranges and, with one-third of births occurring in women .30 years, Poland is at risk for continued occurrence of CRS cases. To reduce this risk and allow for the opportunity to reach elimination, MMR supplemental immunization activities are needed among adolescent and teenage male individuals born from 1991 through 1996. This cohort includes those age cohorts with the highest disease transmission because of missed opportunities for receipt of vaccine (ie, birth during 1995 and 1996) and those who were never targeted by vaccination recommendations. Supplementary immunization activities (SIAs) should also include female individuals born from 1991 through 1996 who do not have documented proof of receipt of a RCV to ensure immunity to rubella during the childbearing years. To ensure that unvaccinated cohorts of children reach the age of vaccination with a low likelihood of sustaining significant levels of transmission, Poland should consider lowering the currently recommended age for the second dose of MMR from 10 years to 6 years, while keeping a recommended dose at 10 years of age until 2013 or, alternatively, check official vaccination records until 2013 and offer vaccine to those who have not received at least 1 dose of a RCV. Rubella surveillance in Poland is currently based on aggregated data, which preclude the ability to assess individual casebased data at the national level. Results of case-based data from 4 of the 16 regions in Poland indicate that ,1% of reported rubella cases are laboratory confirmed. Although laboratory confirmation is considered to be the most reliable evidence of acute disease, a high proportion of nationally reported rubella cases are likely to be true cases because (1) a noteworthy decrease in reported cases occurred since the 2003 advent of a childhood RCV recommendation, (2) the age and sex distribution of reported cases is consistent with age and sex cohorts historically not included in rubella vaccination recommendations, and (3) the likelihood that another disease would affect both male and female children and almost exclusively male adolescents and teenagers is extremely low. A serologic survey of Warsaw schoolchildren that revealed that ,1% of girls and .36% boys did not have rubella antibodies also supports these findings [15] . After the number of cases of rubella decrease further as SIAs are conducted, implementation of rubella case-based surveillance should be feasible and established in Poland, including laboratory testing of .80% of suspected cases, as recommended by WHO [5] .
In addition to rubella surveillance, establishing comprehensive CRS surveillance in Poland is critical to document the impact of the rubella vaccination program and, if necessary, make changes to the elimination strategies. Potential entry points into a CRS surveillance system include (1) identification and follow-up of pregnant women who are suspected to have or receive a diagnosis of rubella (eg, establishing a pregnancy registry to monitor the follow-up of rubella-infected women) and (2) identification of infants born with congenital defects consistent with CRS (eg, performing retrospective studies to document the completeness of reporting and establishing prospective surveillance at maternity hospitals and tertiary referral centers) [16] . Conducting a serosurvey among women of childbearing age might provide additional information on rubella-susceptible cohorts in Poland and help determine the need for other targeted vaccination efforts among age groups at highest risk for resulting CRS.
The measles vaccination and surveillance program in Poland has reached a mature level, with sustained high vaccination coverage, case-based surveillance, and the ability to genetically characterize viruses from persons with reported measles cases [7, 8] . Further integration of measles and rubella components of elimination activities will help address challenges of the rubella program and ensure progress toward the regional goals and will provide the steps toward Poland attaining the population immunity needed to reach and sustain indigenous rubella elimination and protection against CRS. Potential areas for strengthened integration include conducting case-based surveillance for both diseases, testing of measles-or rubellanegative serologic specimens for each other, and ensuring sustained high routine immunization coverage (.95% with both doses of MMR). The introduction school immunization requirements could help with achieving and sustaining high coverage with all routine vaccinations among school-aged children [17, 18] . In addition, engagement of policy decisionmakers in Poland in supporting the WHO European Region's measles and rubella elimination and CRS prevention goals will be crucial [19] . 
